A non-clinical and clinical IUCLID database for 530 pharmaceuticals (part I): Methodological aspects of its development

被引:1
|
作者
Evangelisti, Martina [1 ]
Parenti, Marco Daniele [1 ,3 ]
Varchi, Greta [3 ]
Franco, Jorge [1 ,4 ]
vom Brocke, Jochen [2 ]
Karamertzanis, Panagiotis G. [2 ]
Del Rio, Alberto [1 ,3 ]
Bichlmaier, Ingo [2 ]
机构
[1] Innovamol Consulting Srl, Via San Faustino 167, I-41126 Modena, Italy
[2] European Chem Agcy ECHA, Telakkakatu 6, Helsinki 00150, Finland
[3] Natl Res Council Italy CNR, Inst Organ Synth & Photoreact ISOF, Via P Gobetti 101, I-40129 Bologna, Italy
[4] Genoa Univ, Via Balbi 5, I-16126 Genoa, Italy
关键词
IUCLID database; Animal testing; Human information; Standard product label; Ontology; Effect levels; Endocrine disruption; Repeat-dose toxicity; Carcinogenicity; Reproductive toxicity; Developmental toxicity; Animal-human correlation; New approach methodologies; NAMs;
D O I
10.1016/j.yrtph.2023.105416
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A new IUCLID database is provided containing results from non-clinical animal studies and human information for 530 approved drugs. The database was developed by extracting data from pharmacological reviews of repeatdose, carcinogenicity, developmental, and reproductive toxicity studies. In the database, observed and noobserved effects are linked to the respective effect levels, including information on severity/incidence and transiency/reversibility. It also includes some information on effects in humans, that were extracted from relevant sections of standard product labels of the approved drugs. The database is complemented with a specific ontology for reporting effects that was developed as an improved version of the Ontology Lookup Service's mammalian and human phenotype ontologies and includes different hierarchical levels. The developed ontology contains novel and unique standardized terms, including ontological terms for reproductive and endocrine effects. The database aims to facilitate correlation and concordance analyses based on the link between observed and no-observed effects and their respective effect levels. In addition, it offers a robust dataset on drug information for the pharmaceutical industry and research. The reported ontology supports the analyses of toxicological information, especially for reproductive and endocrine endpoints and can be used to encode legacy data or develop additional ontologies. The new database and ontology can be used to support the development of alternative non-animal approaches, to elucidate mechanisms of toxicity, and to analyse human relevance. The new IUCLID database is provided free of charge at https://iuclid6.echa.europa.eu/us-fda-toxicity-data.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A non-clinical and clinical IUCLID database for 530 phanmaceuticals
    Evangelisti, M.
    Parenti, M. D.
    Varchi, G.
    Franco, J.
    vom Brocke, J.
    Karamertzanis, P. G.
    Del Rio, A.
    Bichlmaier, I.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S50 - S50
  • [2] Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies
    Mustonen, Enni-Kaisa
    Palomaki, Tiina
    Pasanen, Markku
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 90 : 328 - 341
  • [3] The case of Francesco: clinical and non-clinical aspects
    Bani, A.
    [J]. JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA, 2012, 18 (04): : 309 - 314
  • [4] Non-clinical aspects of oligonucleotide drug development: A regulator's perspective
    Jones, D. R.
    [J]. TOXICOLOGY LETTERS, 2018, 295 : S23 - S24
  • [5] Design and deployment of a large brain image database for clinical and non-clinical research
    Yang, GL
    Lim, CCT
    Banukumar, N
    Aziz, A
    Hui, F
    Nowinski, WL
    [J]. MEDICAL IMAGING 2004: PACS AND IMAGING INFORMATICS, 2004, 5 (25): : 124 - 132
  • [6] Methaemalbumin Part I Clinical aspects
    Fairley, NH
    [J]. QUARTERLY JOURNAL OF MEDICINE, 1941, 10 (28): : 95 - +
  • [7] Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals
    Reeve, Lesley M.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2009, 55 (02) : 181 - 187
  • [8] Special non-clinical interests as career development
    Carelli, F
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2003, 53 (492): : 569 - 569
  • [9] Non-clinical development of CER-001
    Barbaras, Ronald
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [10] Predictivity of Non-Clinical Repolarization Assay Data for Clinical TQT Data in FDA Database
    Koerner, J.
    Valentin, J. P.
    Willard, J.
    Park, E. J.
    Bi, D.
    Link, W. T.
    Fiszman, M.
    Kozeli, D.
    Skinner, M.
    Vargas, H. M.
    Cantilena, L.
    Gintant, G.
    Wisialowski, T.
    Pettit, S.
    [J]. INTERNATIONAL JOURNAL OF TOXICOLOGY, 2013, 32 (01) : 63 - 63